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Abstract
Background: The systemic information enclosed in microarray data encodes relevant clues to overcome the poorly
understood combination of genetic and environmental factors in Parkinson’s disease (PD), which represents the
major obstacle to understand its pathogenesis and to develop disease-modifying therapeutics. While several gene
prioritization approaches have been proposed, none dominate over the rest. Instead, hybrid approaches seem to
outperform individual approaches.
Methods: A consensus strategy is proposed for PD related gene prioritization from mRNA microarray data based
on the combination of three independent prioritization approaches: Limma, machine learning, and weighted gene
co-expression networks.
Results: The consensus strategy outperformed the individual approaches in terms of statistical significance, overall
enrichment and early recognition ability. In addition to a significant biological relevance, the set of 50 genes
prioritized exhibited an excellent early recognition ability (6 of the top 10 genes are directly associated with PD).
40 % of the prioritized genes were previously associated with PD including well-known PD related genes such as
SLC18A2, TH or DRD2. Eight genes (CCNH, DLK1, PCDH8, SLIT1, DLD, PBX1, INSM1, and BMI1) were found to be
significantly associated to biological process affected in PD, representing potentially novel PD biomarkers or
therapeutic targets. Additionally, several metrics of standard use in chemoinformatics are proposed to evaluate the
early recognition ability of gene prioritization tools.
Conclusions: The proposed consensus strategy represents an efficient and biologically relevant approach for gene
prioritization tasks providing a valuable decision-making tool for the study of PD pathogenesis and the
development of disease-modifying PD therapeutics.
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Background
Parkinson’s disease (PD) is the second most common
neurodegenerative disorder (ND). The present annual
cost of health care for patients with PD is estimated to
exceed $ 5.6 billion just in the US. With the rapid
increase in worldwide life expectancy, the prevalence of
PD is expected to double by 2030 [1–3].
Dopamine replacement drugs remains the principal and
most effective treatment for PD [4]. However, as the dis-
ease progresses, their efficacy diminishes and fails to ad-
dress the degeneration observed in other brain areas [5–7].
Ultimately, disease-modifying treatments are needed that
address both the motor and nonmotor symptoms of PD.
Currently the most important diagnostic marker of PD
is limited to the presence of motor disturbances. Unfortu-
nately, due to overlap of symptoms with other neurode-
generative disorders, misdiagnosis is common. Moreover,
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motor deficits allowing clinical diagnosis generally appear
when 50–60 % of dopaminergic neurons in the substantia
nigra (SN) are already lost, limiting the effectiveness of
potential neuroprotective therapies [8].
In addition to motor symptoms, non-motor symptoms
including autonomic dysfunction, depression, olfactory
deficit, cognitive disturbances and sleep abnormalities
have been related to PD [9]. This mixture of apparently
unrelated symptoms and physiological disorders high-
light that PD is a multi-causal disorder. Thus, to identify
new targets and biomarkers for PD becomes critical for
the early diagnosis of this medical condition and for the
development of disease-modifying therapies.
In this sense, the systemic picture of gene expression
information enclosed in mRNA microarrays experiments
encodes relevant clues on the pathogenesis, biomarkers
or therapeutics targets for a disease state, but requires of
approaches able to unravel it through the accurate
prioritization of those disease relevant genes [10]. Sev-
eral bioinformatics approaches have been reported for
this task including those based on differential gene ex-
pression [11], gene co-expression networks [12] or ma-
chine learning (ML) approaches [13].
Each approach has particular theoretical foundations de-
termining relative advantages and limitations. It is well
known that the consensus use of multiple and independent
pieces of information increases the reliability of a decision-
making process [14]. So, the hybridization of conceptually
different approaches can provide prioritization tools with
enhanced efficiency [15]. Specifically, such novel hybrid ap-
proaches have not been applied yet to PD relevant genes
prioritization nor even to neurodegenerative disorders [12].
In this work we propose a consensus strategy for PD rele-
vant genes prioritization based on the integration of several
approaches including linear models for microarray data
(Limma), machine learning, and co-expression networks.
Since only a few candidates can usually be considered for
further validation experiments, particular emphasis is made
in the early recognition ability prioritization tools.
One problem benchmarking the early recognition
ability of prioritization approaches in bioinformatics is
the lack of statistically sound metrics for this task
[16]. Other related areas such as chemoinformatics
have standardized procedures to evaluate an analo-
gous problem to gene prioritization, the virtual
screening [17]. Here we propose for the first time the
use of such early recognition metrics to evaluate the
performance of gene prioritization approaches. Hence,
besides to identify an enriched set of PD related
genes we propose a consensus strategy for gene
prioritization with proved enrichment efficiency and
biological relevance, as well as a statistically founded




Experimental microarray data comparing healthy control
(HC) and Parkinson’s disease (PD) samples were obtained
analyzing the Gene Expression Omnibus (GEO) [18].
Table 1 shows the GEO data sources, references, and sam-
ple distribution used in the study. Only studies on sub-
stantia nigra were considered. So, eight samples collected
from frontal gyrus were removed from GSE8397.
It is important to highlight that the substantia nigra is
the region of the brain that shows the greatest loss of
dopaminergic neurons in human PD patients. This in-
duce a serious bias that we will term the “dopamine
bias”. This bias induce a serious risk of overestimation
of the enrichment ability of a prioritization strategy
based on samples coming from the substantia nigra. At
the same time, it is also true that dopamine-related
process are intrinsically implicated in the pathogenesis
of PD. So, we need to check not only which prioritized
gene is “dopamine-related”, but also whether such gene
is associated or not with PD. This critical issue will be
considered along all the analysis conducted and properly
discussed in the following sections of the manuscript.
Each microarray was processed as follows: public data
was extracted and processed using GEOquery package in
Bioconductor [19]. After individual microarrays analysis,
the first step in cross-platform microarray analysis is to
combine the different probes. For this task the entrez
gene was used as identifier in order to obtain the com-
mon space across all platforms [20–22]. We mapped the
arrays probes of each independent studies to the respect-
ive entrez gene ID through manual observation and also
using the updated manufacturers annotation information
(using R-packages: hgu133a.db, hgu133plus2.db and
hgfocus.db [23–25]) for all platforms.
Only genes common to all platforms (8477 genes)
were used in the subsequent analysis. Genes with more
than one probe in individual microarray/studies were
combined using the row with the highest mean intensity
value applying the collapseRows and intersect functions
implemented in the WGCNA package [26, 27]. A second
normalization was performed in order to re-scale the
intensity and remove cross-platform batch effects using
the Combat function of the SVA package [28]. From the
Table 1 Microarray data details
Code Platform Sample Ref.
GSE20292a GPL96 11(PD); 18(HC) [45, 53]
GSE7621 GPL570 16(PD); 9(HC) [46]
GSE20333 GPL201 6(PD); 6(HC) [97]
GSE8397b GPL96 31(PD); 16(HC) [47]
aThree samples with outlier nature removed after cross-platform normalization
bEight samples collected from frontal gyrus removed
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initial set of 29 samples in GSE20292 three samples
with outlier nature were removed after cross-platform
normalization. Finally a subset of 102 samples (59 PD
and 43 HC) remained for further analysis.
Differential gene expression analysis
The identification of genes with statistically different ex-
pression between HC and PD groups was performed
using lmFit from Limma R-Package [29]. The basic stat-
istic used for significance analysis was the moderated t-
statistic after adjustment with the Benjamini and Hoch-
berg’s method to control the false discovery rate (“fdr”
adjusted p-values) [30].
Machine learning analysis
The ML analysis was conducted over a cross-platform
normalized microarray data including 8477 common
genes for 102 samples. The full data was split up into
training and test sets, as part of the validation scheme
[31]. Approximately 25 % of the samples were randomly
assigned to the “Test Set” by using the Create a Subset/
Random (Stratified) Sampling option implemented in
STATISTICA 8.0 [32]. Details on the final distribution
of the 102 samples can be assessed on Additional file 1:
Table S1. Normalized expression values of the 8477
common genes for each of the 102 samples, sample and
study identifiers, disease factor (PD or HC), as well as
the distribution of training and test samples are provided
as supplementary information Additional file 2.
The full vector of 8477 normalized gene expression
values was reduced to 500 genes with maximal relevance
for the disease factor by means of the minimal redundancy
maximal relevance (mRMR) software [33]. Details of the
reduced gene set by using the mRMR software are pro-
vided in the supplementary information. Then, the re-
duced vector was subject to an independent process of
feature selection relying on eleven different ranking fea-
ture selection algorithms implemented on WEKA 3.7.11
[34]. See the full list of attribute evaluators in the supple-
mentary information. Additionally, the reduced vector
was subject to a wrapper subset selection using as attri-
bute evaluators only those ML classifiers including a sub-
set feature selection stage implemented on WEKA 3.7.11.
Weighted gene co-expression network construction and
analysis
The full set of 8477 common genes was used for
weighted genes co-expression network (WGCN) con-
struction in each group using the WGCNA package [27].
In this study, we set the β parameter variation to 6, fol-
lowing the scale-free topology criterion proposed by
Zhang and Horvath using the pickSoftThreshold function
in WGCNA [35]. Once defined the adjacency matrix for
each group (HC and PD), the corresponding co-
expression matrices (CoHC and CoPD) were obtained.
Modular analysis
The modules were detected using the Dynamic Tree Cut
algorithm [36] by using the cutreeDynamic function im-
plemented in the WGCNA package. Here, the deep split
was set to 3, the cutting height to the 99th percentile
and the joining heights on the dendograms were set to
the maximum. The node connectivity (k) and the node
intramodular connectivity (kintra) were calculated for
each module as described in [37].
Statistical significance
The gene ontology (GO) and diseases enrichment ana-
lysis were performed using DAVID bioinformatics re-
source v6.7 [38], exploiting the well know Gene
Ontology Annotation (GOA) [39] and Genetic Associ-
ation (GAD) [40] databases. The ToppCluster tool for
the combined enrichment analysis [41] was used to pro-
vide network representations of individual and common
terms. The statistical significance of the respective en-
richment analyses was accessed by using FDR criteria
with p-value < 0.05 as cut-off.
The statistical significance of each genes set prioritized
as relevant for PD was assessed as proposed by Chen et
al. [42, 43]. Detailed information on the application of
this test is provided in the supplementary information.
Additionally, a bootstrap random sampling experiment
was implemented in R as proposed by [42, 43] and per-
formed to test the probability of randomly selecting the
same number of known PD related genes in the priori-
tized genes sets. The Wilcoxon signed rank test was
used as significance test.
Enrichment and early recognition
Several enrichment metrics have been proposed in the
chemoinformatics literature to measure the enrichment
ability of a VS protocol [17]. However, despite being bio-
informatic’s gene prioritization and chemoinformatic’s
virtual screening essentially the same problem, this type
of enrichment analysis has not been applied in bioinfor-
matics. In this work, we use some of the most extended
metrics to estimate the enrichment ability of the gene
prioritization strategies proposed. The overall enrich-
ment metrics used here include the area under the accu-
mulation curve (AUAC); the area under the ROC curve
(ROC); and the enrichment factor (EF) evaluated at the
top 1 %/5 %/10 %/20 % of the ranked list. At the same
time, the early recognition metrics used were the robust
initial enhancement (RIE) and the Boltzmann-enhanced
discrimination of ROC (BEDROC) evaluated at the
top 1 %/5 %/10 %/20 % of the ranked list [17]. The
calculation of both classic and early recognition
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enrichment metrics was conducted by using the perl
script Cresset_VS [44].
Results and discussion
Limma based gene prioritization
First, the background of 8477 genes provided by the 102
samples of HC and PD patients was processed with
Limma. The goal here is to identify those single genes
significantly differentiated between HC and PD samples
and so, potentially associated with PD. This procedure
identified a set of 134 genes with an “fdr” adjusted p-
values < 0.05, each of which was considered to be signifi-
cantly differentiated on PD patients. Details on this set
of genes are reported as supplementary information. The
results of the disease enrichment analysis are shown in
Table 2. The number of genes associated with PD and
included in GAD provides evidence of a statistically sig-
nificant association of the selected set of genes with PD
(p-value = 0.0271).
It is important to note that the GAD database only
covers 29 % of the top 134 genes prioritized using an
FDR corrected p-value < 0.05 as significance cutoff. Simi-
larly, the OMIM database have only a coverage of just
25 %. Accordingly, the ranking provided by the disease
enrichment analysis must be used as reference instead of
a exact criterion of the degree of association of the pri-
oritized genes set with the disease. Consequently, the in-
formation in Table 2 can be only used to support the
statistically significant association between the top 134
genes prioritized by Limma and PD.
However, if we use an uncorrected p-value < 0.5 as a
significance cutoff instead of the FDR corrected p-value,
the set of prioritized genes increases notably to 1016
genes with a non statistically significant association with
PD (data not shown). Such a radical change supports the
choice in this work to use FDR corrected instead of un-
corrected p-values. It could be explained by the well-
knwon ability of the FDR correction to minimize the
number of false negatives [30] which minimize the lost
of PD related genes and consequently, increasing the en-
richment of the gene set selected by using this criterion.
The full list of the top 1016 genes prioritized are pro-
vided as a suplementary information (see Additional file
5). In this list we can find several genes reported in pre-
vious transcriptome analysis based on similar samples
[45–51], some using the same micrarray data used in
our work. Even so, it is hard to know the real degree of
overlapping between our genes and those reported in
these works because not every paper reports the full list
of significantly differentiated genes. Moreover, in these
works several dissimilar processing strategies were ap-
plied which impose and additional degree of difficulty
on the comparison across these and our study.
If we look for example to the works reported in
[47, 48, 51, 52], the degree of overlaping between the
genes lists reported is extremely low. Actually, no
common genes were found between the four studies
and the maximal overlapping between two studies
were two common genes (LRRFIP1 and MDH1) be-
tween [5] and [6]. Such a minimal degree of overlap-
ping could be atributed to the diversity of tissues,
samples or methodological approaches applied on
each independent study. However, when the unique
set of 243 genes extracted from the combination of
the genes sets reported in [47, 48, 51, 52] is com-
pared with our genes prioritized with Limma, a sig-
nificantly higher degree of overlaping is found.
Specifically, a 4.92 % of overlapping (50 common
genes) is found considering the top 1016 genes (using
the uncorrected p-value < 0.05 as a significance cut-
off ); 8.21 % of overlapping (11 common genes)
considering the top 134 genes (using FDR corrected
p-value < 0.05); and 6.49 % of overlapping (39 com-
mon genes) considering the top 608 genes (using
FDR corrected p-value < 0.25). The last top fraction of
608 genes using a cutoff of 0.25 for FDR corrected p-values
was also included in the comparison since such a cutoff is
widely used in this type of prioritizations [47–50, 53]. One
should expect a higher degree of overlapping for larger
gene sets. However, as described, the higher degree of over-
lapping was found in the top 134 genes prioritized by using
FDR corrected p-values. Again, the ability of the FDR
Table 2 Disease enrichment analysis on the Genetic Association











bipolar disorder 0.0030 7 39 96 2459
schizophrenia 0.0034 11 39 249 2459
alcohol abuse 0.0227 4 39 40 2459




0.0307 2 39 2 2459
schizophrenia;
opium abuse
0.0307 2 39 2 2459




0.0457 2 39 3 2459




0.0457 2 39 3 2459
personality traits 0.0480 3 39 23 2459
Hits Sample: Number of genes selected by Limma that are asociated with the
disease condition; Total Sample: Number of genes selected by Limma; Hits
Background: Number of genes in the background that are asociated with the
disease condition; Total Background: Number of genes in the background
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correction to minimize the number of false negatives can
be the explanation to this unexpected observation.
Other genes known to be associated with PD such as
TH, SLC18A2, NR4A2, DDC and SLC6A3 can be found
in our Limma prioritization. Interestingly, compared
with these genes, SNCA exhibited a lower significance.
An statistically significant differenced expression of
SNCA is considered mandatory for clinical diagnosis of
classical PD [8, 48]. In this prioritization we noted this
differencial expression (see supplementary information),
but just using as a cutoff an adjusted p-value < 0.25, in
agreement with previous studies [47–50, 53]. On the
other hand, a reduction in dopamine markers as well as
the the presence of α-synuclein–positive Lewy bodies in
substantia nigra are not exclusive of PD [8, 54]. There-
fore it is not surprising that the consensus approach pri-
oritized other genes before SNCA.
A different scenario emerges from the GO enrichment
analysis of biological proceses. From this analysis, the
overall information extracted is that although the set of
genes prioritized by Limma do not fully match with
known genes associated with PD, the biological processes
involving these genes are well known to be implicated in
the pathogenia of PD. The GO terms, description, and the
FDR corrrected p-values corresponding to the top 11 sta-
tistically significant biological process identified from the
set of 134 genes are provided in Table 3. Details on the full
list of biological process associated to this gene set can be
accessed in the suplementary information (see Additional
file 5).
The information provided in Table 3 clearly reveals an
enrichment in dopamine and neurotransmition process. Al-
though the key role of dopamine metabolism in PD is well
known [6], the reduction of dopamine synthesis or simply
changes in the metabolism of the dopamine are not exclu-
sive of PD. Such effect in other neurodegenerative disorders
or even aging has been recently discussed [51]. Addition-
ally, we can not rule out that the enrichment observed in
dopamine process could be a possible consequence of a
particular degradation in the substantia nigra or even a
combined factor for neuronal loss in this particularly sens-
ible tissue [48, 50]. Obviously, is not possible to isolate
these effects without aditional experimental data. We also
found (although with FDR corrected p-values < 0.05) other
biological process well stablished in PD such as oxidative
fosforilation and energetic metabolism [46–49, 53] (see de-
tails in the supplementary information). The lack of statis-
tical significance of these process is obviously a direct
consequence of the reduction of the gene set comming
from the use FDR corrrected p-values as cutoff. Actually,
when the entire set of 1016 genes (using uncorrected
p-values) is subject to the same GO enrichment ana-
lysis, these processes become significantly more
enriched than dopaminergic processes. The details on
the GO enrichment analysis are provided as supple-
mentary information (see Additional file 5). This also
indicates that even when a bias toward dopamine me-
tabolism exist, additional information relevant to PD
is enclosed in the microarray data used. As discussed
later, the consensus strategy actually favor the inclu-
sion of such non dopamine related process.
Finally, another important finding to mention is that
the transcriptional coactivator PPARGC1A (PGC-1α)
was not found to be significantly differenciated in our
study, even when it is a master regulator of mitochon-
drial biogenesis and oxidative metabolism [48, 50]. In
this sense, it is important to note that these studies ap-
plied different methodologies so to find this gene as not
significantly differentiated is a perfectly possible sce-
nario. The fact that only one of the four studies used in
this work reported this gene as diferentially expressed
support this observation. Finally, even when PPARGC1A
was not found in our study, several genes were found to
be direct interactors, and biological process directly re-
lated with this gene are clearly present in our prioritized
genes. It is elaborated further based on the results shown
by the functional interaction network of the set of 50
genes finally prioritized.
Machine learning based gene prioritization
For the ML based gene prioritization process, the full
vector of 8477 normalized gene expression values was
first reduced to 500 genes with maximal relevance for
the disease factor (see the full list in the Additional file
3). This set of 500 genes comprises the 91 % of the 134
genes prioritized by Limma. This indicates that this ini-
tial gene set used as input for feature selection and fur-
ther ML modeling conserves almost the same information
Table 3 GO terms, description, and the FDR corrrected p-values
corresponding to the statistically significant biological process
identified from 134 genes prioritized by Limma
GO terms Description p-value
(FDR)
GO:0006576 biogenic amine metabolic process 3,3E-04
GO:0042401 biogenic amine biosynthetic process 3,7E-04
GO:0034311 diol metabolic process 8,2E-04
GO:0009712 catechol metabolic process 8,2E-04
GO:0006584 catecholamine metabolic process 8,2E-04
GO:0018958 phenol metabolic process 9,8E-04
GO:0042423 catecholamine biosynthetic process 3,2E-03
GO:0042398 cellular amino acid derivative biosynthetic
process
1,4E-02
GO:0042416 dopamine biosynthetic process 2,3E-02
GO:0006575 cellular amino acid derivative metabolic
process
2,9E-02
GO:0042417 dopamine metabolic process 4,4E-02
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prioritized by Limma. Then, the reduced vector was subject
to an independent process of feature selection as previously
depicted in Methods section. Once ranked the 500 relevant
genes by the respective attribute selection method, each
gene is scored according to their mean rank position across
the eleven attribute evaluators by applying a desirability
function [55]. The corresponding gene relevance score
d(Ranki) is defined as:
d Rankið Þ ¼ Ranki−11−Rankmax 0 ≤ d Rankið Þ ≤1 ð1Þ
Here Ranki denotes the rank position assigned to the
gene i by the attribute evaluator while Rankmax is deter-
mined by the number of genes to rank and corresponds to
the worst possible rank position (500th). Finally, the overall
relevance score for a gene i deduced from the consensus
ranking analysis D(Ranki) is computed as the arithmetic
mean of the d(Ranki) values across all the attribute evalua-
tors applied.
Next, the 500 genes previously identified were also
subject to a wrapper subset selection as described in
Methods section. The relevance of the subset of genes
selected is deduced from the accuracy of the respective
classifier. So, we only considered as relevant those subset
of genes coming from classifiers exhibiting values of ac-
curacy, sensitivity and specificity over 0.6 on training and
validation sets. Table 4 provides details of the predictive
performance of the thirteen ML classifiers. Considering
the classification performance we can assert that based on
the set of genes identified by each ML algorithm it is pos-
sible to classify the disease status of our microarray sam-
ples with a confidence ranging from 75 to 83 % (see
Table 4). The sets of genes selected by the respective clas-
sifiers are provided in Additional file 1: Table S2.
Again, by applying a desirability function is possible to
score the relevance of the respective gene according to
the number of valid classifiers including the gene i and
so, considering it as relevant. The corresponding gene
relevance score based on the consensus classifier analysis
d(Classi) ranges between 0 (only one valid classifier in-
cludes the gene) and 1 (the gene is considered relevant
by all the valid classifiers) and is defined as:
d Classið Þ ¼ Nreli−1NClass−1 0 ≤ d Classið Þ ≤1 ð2Þ
Here Nreli denotes the number of valid classifiers in-
cluding the gene i while NClass indicates the number of
valid classifiers.
Table 4 Classification performance of the ML classification algorithms used to identify PD relevant sets of genes
ML Classification Algorithm Training set LOO CV 5-Fold CV Test set
Acc. Se. Sp. Acc. Se. Sp. Acc. Se. Sp. Acc. Se. Sp.
functions.SimpleLogistic 1.000 1.000 1.000 0.827 0.860 0.781 0.827 0.814 0.844 0.704 0.750 0.636
rules.MODLEM 1.000 1.000 1.000 0.813 0.837 0.781 0.760 0.767 0.750 0.778 0.750 0.818
rules.PART 0.987 0.977 1.000 0.653 0.674 0.625 0.747 0.721 0.781 0.741 0.750 0.727
trees.ADTree 1.000 1.000 1.000 0.853 0.860 0.844 0.787 0.721 0.875 0.741 0.750 0.727
trees.BFTree 0.973 1.000 0.938 0.853 0.884 0.813 0.747 0.744 0.750 0.741 0.750 0.727
trees.FT 1.000 1.000 1.000 0.800 0.837 0.750 0.867 0.884 0.844 0.741 0.813 0.636
trees.LADTree 1.000 1.000 1.000 0.840 0.884 0.781 0.827 0.814 0.844 0.889 0.875 0.909
trees.LMT 1.000 1.000 1.000 0.813 0.860 0.750 0.773 0.767 0.781 0.741 0.813 0.636
trees.SimpleCart 0.973 1.000 0.938 0.827 0.837 0.813 0.747 0.721 0.781 0.741 0.750 0.727
meta.AdaBoostM1 1.000 1.000 1.000 0.840 0.884 0.781 0.880 0.907 0.844 0.926 1.000 0.818
meta.AttributeSelectedClassifier 0.960 0.977 0.938 0.680 0.721 0.625 0.760 0.767 0.750 0.852 0.875 0.818
meta.ClassificationViaRegression 0.960 0.977 0.938 0.813 0.814 0.813 0.733 0.698 0.781 0.815 0.938 0.636
meta.Decorate 1.000 1.000 1.000 0.893 0.860 0.938 0.867 0.837 0.906 0.963 1.000 0.909
AVERAGE 0.989 0.995 0.981 0.808 0.832 0.777 0.794 0.782 0.810 0.798 0.832 0.748
Acc. = accuracy or overall classification rate; Se. = sensitivity or true positives rate (% of PD samples correctly classified); Sp. = specificity or true negatives rate
(% of HC samples correctly classified)
functions.SimpleLogistic: Classifier for building linear logistic regression models [104]; rules.MODLEM: Class for building and using a MODLEM algorithm to induce
rule set for classification [105]; rules.PART: Class for generating a PART decision list [106]; trees.ADTree: Class for generating an alternating decision tree [107];
trees.BFTree: Class for building a best-first decision tree classifier [108]; trees.FT: Classifier for building ‘Functional trees’, which are classification trees that could have
logistic regression functions at the inner nodes and/or leaves [109]; trees.LADTree: Class for generating a multi-class alternating decision tree using the LogitBoost
strategy [110]; trees.LMT: Classifier for building ‘logistic model trees’, which are classification trees with logistic regression functions at the leaves [104, 111]; trees.
SimpleCart: Class implementing a classification and regression tree with minimal cost-complexity pruning [112];meta.AdaBoostM1: Metaclassifier class for boosting a nominal
class classifier using the Adaboost M1 method [113]; meta.AttributeSelectedClassifier: Metaclassifier class where dimensionality of training and test data is reduced by attribute
selection before being passed on to a classifier http://weka.sourceforge.net/doc.dev/weka/classifiers/meta/AttributeSelectedClassifier.html;meta.ClassificationViaRegression:
Metaclassifier class for doing classification using regression methods [114];meta.Decorate: Meta-learner for building diverse ensembles of classifiers by using specially
constructed artificial training examples [115, 116]
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The final subset of relevant genes proposed by the ML
prioritization strategy is determined by 168 unique genes
forming the union of the subsets of genes identified by
the valid classifiers. Finally, the absolute relevance of
each gene (MLreli) is estimated by considering its re-
spective D(Ranki) and d(Classi) scores and quantified as
the corresponding arithmetic mean. Details on this set
of genes are reported as supplementary information (see
Additional file 4).
The final result is a list of 168 unique genes (see Add-
itional file 5) with proved capability of discriminating PD
from HC samples, and sorted according to their consen-
sus merit (MLreli). This ML set was subject to a disease
enrichment analysis, providing evidence of a statistically
significant association of the selected genes with PD, pla-
cing PD 2nd in the list, with p-value = 0.0367. However,
none of the biological process involved in this set of genes
was statistically significant. It is important to note that
ML methods are focused on maximizing the correct clas-
sification rate. So, contrary to standard prioritization
methods based on gene expression data, the set of genes
identified with ML favor the relevance for the disease state
instead the gene connectivity information or the biological
background. Accordingly, it is unlikely that the final gene
list prioritized by ML methods provide statistically signifi-
cant enrichments of biological processes or pathways.
Table 5 Connectivity, differential expression and machine learning data used as criteria for module prioritization
Healthy Control (HC) Modules
Module n <k> <kintra> <logPD-logHC> nML Merit_ML nLimma Merit_Limma nML-Limma Merit_ML-Limma
HC_01 123 12.04 1.38 −0.021 3 1.23 1 0.51 1 1.23
HC_02 349 34.57 7.29 −0.061 6 0.87 13 2.36 4 1.73
HC_03 1057 19.04 8.85 0.011 4 0.19 2 0.12 2 0.29
HC_04 169 17.02 2.59 −0.002 1 0.30 0 0.00 0 0.00
HC_05 347 9.23 2.59 0.165 2 0.29 1 0.18 1 0.44
HC_06 74 8.26 0.73 0.005 0 0.00 0 0.00 0 0.00
HC_07 290 14.81 5.19 0.073 4 0.70 6 1.31 1 0.52
HC_08 251 10.94 2.05 0.030 11 2.21 10 2.52 5 3.02
HC_09 2 1.15 0.00 0.022 0 0.00 0 0.00 0 0.00
HC_10 37 15.32 1.48 0.043 1 1.36 0 0.00 0 0.00
HC_11 91 10.95 1.23 0.048 3 1.66 0 0.00 0 0.00
HC_12 61 23.65 3.85 0.028 2 1.65 0 0.00 0 0.00
HC_13 164 10.23 1.79 0.007 3 0.92 1 0.39 1 0.92
HC_14 71 8.33 0.81 −0.001 0 0.00 0 0.00 0 0.00
HC_15 2120 49.53 36.69 −0.062 82 1.95 97 2.89 40 2.86
HC_16 3271 22.06 14.66 −0.064 46 0.71 3 0.06 1 0.05
Parkinson’s Disease (PD) Modules
PD_01 603 286.30 70.52 0.022 6 0.50 1 0.10 1 0.25
PD_02 1437 262.21 150.85 −0.126 69 2.42 103 4.53 42 4.42
PD_03 133 210.12 13.36 0.035 1 0.38 0 0.00 0 0.00
PD_04 161 284.83 22.96 0.089 4 1.25 3 1.18 2 1.88
PD_05 789 231.70 62.45 −0.025 5 0.32 1 0.08 0 0.00
PD_06 468 238.37 38.64 0.132 3 0.32 0 0.00 0 0.00
PD_07 494 316.82 58.43 0.103 24 2.45 19 2.43 8 2.45
PD_08 213 218.15 28.17 −0.033 4 0.95 2 0.59 1 0.71
PD_09 4179 333.39 247.08 −0.047 52 0.63 5 0.08 2 0.07
n: number of genes in the module; <k>: average node degree; <kintra>: intra-modular average node degree; <logPD-logHC>: module average differential of the log
transformed average expression of a gene i across PD samples and healthy control samples; nML: number of genes identified by ML analysis included in the mod-
ule; nLimma: number of genes identified by Limma analysis included in the module; nML-Limma: number of common genes identified by both ML and Limma analyses
included in the module; Merit_ML = (nML/168)/(N/8477): merit assigned to the module based on nML, the total number of genes identified by ML analysis (168),
N, and the total number of background genes (8477); Merit_Limma = (nLimma/134)/(N/8477): merit assigned to the module based on nLimma, the total number of
genes identified by Limma analysis (134), N, and the total number of background genes (8477); Merit_ML-Limma = (nML-Limma/56)/(N/8477): merit assigned to the
module based on nML-Limma, the total number of common genes identified by both ML and Limma analyses (56), N, and the total number of background genes (8477)
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Gene co-expression network modules prioritization
Using the Dynamic Tree Cut method, 9 and 16 modules
were identified in CoHC and CoPD, respectively. Details
on the connectivity profile of both co-expression net-
works are provided in Table 5.
Based on the connectivity information it should be
possible to identify those modules enriched with hub
genes [56, 57]. In this sense, relatively high values of the
modules average node (gene) degree (<k>) as well as the
average intramodular node degree (<kintra>) can act as
relevant indicators of modules potentially enriched with
hub genes. From the connectivity information four po-
tentially PD relevant modules are identiffied. PD_07,
PD_01, and PD_04 exhibit particularly high values of
<k> while modules PD_02, and PD_01 show significantly
high values of <kintra>. Among these four modules
PD_07 stands out as the module with the highest overall
connectivity but with barely high intramodular connect-
ivity. On the other hand PD_02 exhibits a significant but
inverse profile.
A solid decision can’t be made on the only basis of the
connectivity information. So, additional information
needs to be considered. For this we focused on the dif-
ferential of the log transformed average expression of a
gene i across PD samples and HC samples (logPD-
logHC). The goal here is to identify modules enclosing
Fig. 1 a Box plot of the differential average expression of genes across PD and healthy control samples (logPD-logHC) for genes conforming the
nine PD WGCN modules. b Line plots of logPD-logHC for all the 8477 genes used to construct the global PD WGCN (center), 1437 genes in the
predominantly underexpressed PD WGCN module PD_02 (left), and 494 genes in the predominantly overexpressed PD WGCN module PD_07 (right)
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genes significantly associated with PD and involved in
common biological process that are central in PD [58].
Based on the average logPD-logHC value (see Table 5),
PD_02 stands out as a significantly underexpressed mod-
ule while PD_07 toguether with PD_06 are the most
overexpressed modules. However, only PD_02 and
PD_07 should be selected. From Fig. 1a it is clear that al-
though PD_06 exhibit a slightly higher average logPD-
logHC value, a significant amount of genes with outlier
and extreme behaviour are only present in PD_07. From
Fig. 1b it is possible to visually confirm that most of the
underexpressed genes in the background (center) be-
longs to PD_02 (left) while most of the overexpressed
genes belongs to PD_07 (right).
It is well known that the consensus use of multiple and
independent pieces of information increases the reliability
of a decision-making process [14]. So, based on the en-
richment potential demonstrated by Limma and ML it is
feasible to expect a significant confidence gain by incorp-
orating these two independent approaches. From Table 4
can be confirmed the relevance of PD_02 and PD_07 for
PD from a ML and/or Limma perspective. Here, we use
an intuitive measure of the merit of each module based on
the number of genes in the module identiffied by each ap-
proach. The merit values of ML and/or Limma associated
to PD_02 and PD_07 outperform from 1.3-fold to 3.8-fold
the closest module (PD_04).
Statistical Significance. In order to statistically valid-
ate our module prioritization strategy each WGCN PD
module was subject to a hypergeometric probability test.
Detailed results are provided in Table 6. From this table
it is possible to note that only PD_02 is enriched in PD
related genes significantly beyond what might be ex-
pected by chance (p-value = 0.0034) while PD_07 is in
the limits of the statistical significance (p-value =
0.0512). These results support the strategy followed for
modules prioritization. Regarding to the inclusion of the
module PD_07, as previously mentioned, the GAD data-
base was used just as a common reference framework
for comparison purposes. Therefore, the p-values re-
ported must be used as a decision-making criterion in-
stead of a definitive selection/rejection criterion. On the
other hand, the biological relevance of this module also
grants its inclusion as will be demonstrated in the fol-
lowing section.
Biological Relevance. The space of biological process
covered by the respective PD_02 and PD_07 gene sets was
explored by conducting a joined gene ontology (GO) en-
richment analysis in order identify commonalities and
uniqueness between these two modules. The association
between the corresponding biological process and PD
were contrasted with the current literature evidence. The
full details on the enrichment analysis are provided as
supplementary information (see Additional file 5).
From this analysis four processes well known to be
associated with PD can be highlighted from the 1437
genes included in the module PD_02: oxidative phos-
phorylation; intracellular transport; mitochondrion
organization; and learning or memory. These results re-
flect the well-known mitochondrial complex I deficiency
[59] (specifically, primary defects in mitochondrial oxi-
dative phosphorylation [60]) leading to oxidative stress,
largely associated to PD and their characteristics motor
and cognitive impairments [59–63]. In terms of bio-
logical processes, the information provided by the genes
included in this module and those prioritized by Limma
is highly consistent. Even so, contrary to Limma
prioritization, this module do not enrich mainly dopa-
mine metabolism processes but also energetic process.
This suggest that the dopamine bias could be actually
compensated by combining Limma and co-expression
analysis.
From the 494 genes involved in PD_07 three processes
well known to be associated with PD can be highlighted:
protein folding; response to unfolded protein; and re-
sponse to protein. These processes had being largely re-
ported by other authors [48, 49, 53] and could be
associated with the role of α-Synuclein misfolding and
aggregation in the pathogenesis of PD [64].
A combined enrichment analysis of the biological
process comprised in PD_02 and PD_07 was con-
ducted with aid of the ToppCluster tool [41] (see de-
tails in the Additional file 5). The resultant network
representation of individual and common biological
process for PD_02 and PD_07 is provided in Fig. 2.
As can be noted in this figure, both modules share
common biological processes including the influence
in protein phosphorylation, apoptosis and protein
Table 6 Hypergeometric test results for the WGCN PD modules
based on 319 known PD related genes in GAD and 8477
background genes
Prioritized PD Module n m p-value
PD_01 603 29 0.1014
PD_02 1437 73 0.0034
PD_03 133 6 0.3849
PD_04 161 6 0.5685
PD_05 789 19 0.9897
PD_06 468 15 0.7776
PD_07 494 26 0.0512
PD_08 213 10 0.2813
PD_09 4179 128 0.9997
PD_02 ∪ PD_07 1931 99 0.0003
n: number or genes in the prioritized PD module; m: number of known PD
related genes in GAD found in the prioritized module; p-value: hypergeometric
probability of finding by chance k or more known PD related genes in a set of
n prioritized genes
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metabolism. Some of these processes, such as oxida-
tive phosphorylation and apoptosis has been extensively
reported in PD [46–49, 51, 53], while other process mainly
related with post-translational and post-transcriptional
modifications have been less explored in PD [48, 49].
For example, SNCA is present in PD_02, however,
most of the histones and chaperones are located in
PD_07. Specifically the heat shock protein family B
(small) member 1 (HSPB1) is included in PD_07. This
gene has long been associated with PD [53, 65]. In
addition to protein folding this gene is also involved in
the apoptosis pathway (11) which is common to both
modules. While PD_02 mainly covers energetic and syn-
aptic biological process (oxidative fosforilation, energy
metabolism, synaptic transmision and memory), PD_07
is more focused in processes related with folding and
transcription regulation origins (protein folding; re-
sponse to unfolded protein; and response to protein). By
considering both modules we are covering not only
common biological processes relevant for PD but also
other process equally relevant for PD but uniquely cov-
ered by the respective module. So, PD_07 not only
covers biological process significantly related to PD but
also includes some biological process equally significant
for PD which are not covered by PD_02.
Consensus gene prioritization strategy
The results obtained in WGCN modules prioritization
suggest that the consensus use of several independent
sources of information significantly contribute to identify
genes sets statistically and biologically relevant to PD. In
doing so, all the independent prioritization analyses made
(Limma, ML, and WGCN analyses) were combined in a
consensus gene prioritization strategy. Finding a consen-
sus based on all these tools can provide reliable, statisti-
cally significant and biologically relevant genes sets highly
enriched with already known and potentially novel PD re-
lated genes [14]. The proposed consensus strategy is really
simple, but also highly effective as will be demonstrated:
Only those genes jointly identified by ML and Limma
analysis (common genes) and also present in the
biologically relevant WGCN modules PD_02 or PD_07
can be considered as statistically and biologically
relevant for PD.
This consensus strategy based in the common inter-
ception of three conceptually different prioritization
strategies is actually a highly stringent approach. How-
ever; such stringent criteria should provide a desirable
balance of enrichment and biological significance of the
prioritized gene list.
Our strategy provides a genes list sorted in decreasing
order of probability of association with PD by applying
fusion rules (Min- and Mean-Rank) based on Limma
and ML ranks. That is, genes are first sorted according
to the minimum rank assigned by ML and Limma, and
then by the average of ML and Limma ranks.
Following the proposed consensus strategy was priori-
tized a set of 50 genes sorted in a decreasing order of
Fig. 2 Representative common and unique biological process covered by modules PD_02 and PD_07
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relevance for PD. Details on this genes set are provided
in Additional file 1: Table S3. As can be noted in the
table, 7 out 50 (TP rate = 14 %) genes were found in the
set of 319 known PD related genes in GAD. However,
after an exhaustive literature search for associations be-
tween each of the 50 genes and PD was possible to es-
tablish direct associations for 20 genes in this prioritized
set (TP rate = 40 %).
Statistical Significance. The statistical validity of the
consensus strategy needs to be challenged and compared
with the rest of the alternative gene prioritization op-
tions. For this, the hypergeometric test, and the random
bootstrap sampling were applied to the genes set priori-
tized by the consensus strategy, the ML and Limma ana-
lysis (independently and in combination) as well as to
the genes set corresponding to PD_02 and PD_07 (inde-
pendently and in combination). See details in Table 7.
As deduced from the hypergeometric test, not every
genes set prioritized can be considered as statistically
significant. Although “PD_02 ∪ PD_07” looks like the
better option, its significantly higher number of genes
compared with “Consensus” hinders its potential for
prioritization tasks. Actually, the TP rate of the “Consen-
sus” strategy with only 50 genes is almost three-folds.
Based on the random bootstrap sampling experiment
no genes set seems to be randomly enriched with known
PD related genes. Again, the consensus strategy stands
out for a significantly higher enrichment with known PD
related genes compared with the corresponding random
enrichment determined in the experiment (Fold-Enrich-
ment). The consensus strategy is about four times more
enriched in known PD related genes than might be ex-
pected by chance, which is almost two-fold compared
with “Limma”, the nearest strategy according to Fold-
Enrichment.
Enrichment and Early Recognition Ability. Due to the
high cost associated to the experimental validation of
gene-disease associations and the high number of
candidate genes initially considered (thousands), the
early recognition ability of a gene prioritization tool
should be considered as the ultimate measure of its util-
ity [16]. The estimation of the early recognition ability
by statiscally sound metrics is well established in che-
moinformatics as part of the validation of virtual screen-
ing tools. In this work we propose, for the first time, the
use of such metrics for gene prioritization tasks.
From the accumulation curve we can deduce overall
enrichment from the area under this curve (AUAC)
which is defined as:




where n is the total number of known disease-related
genes in the total background gene set (N) and xi is the
relative rank of the i-th known disease-related gene in
the ordered list when their corresponding rank ri is
scaled to N, (xi = ri/N). So, AUAC can be interpreted as
the probability that a known disease-related gene, se-
lected from the empirical cumulative distribution func-
tion defined by the rank-ordered list, will be ranked
before a gene randomly selected from a uniform distri-
bution [17].
The (Receiver Operating Characteristic) ROC curve
describes the true positives rate (TP rate) for any pos-
sible change of the number of selected genes as a func-
tion of the false positives rate (FP rate) [66]. The area
under the ROC curve (ROC) can be interpreted as the
probability that a known disease-related gene will be
ranked earlier than a disease-unrelated gene within a







where Ra = n/N, and stands for the ratio of known
disease-related genes in the dataset, whereas Ri =N-n/N,
Table 7 Statistical validation of the different gene prioritization strategies employed in this work (independently and in combination).
Hypergeometric test, random bootstrap sampling experiment and enrichment features of the different gene prioritization strategies
Hypergeometric Test Random Bootstrap Sampling (100 Generations) Enrichment
n m p-value Mean Median Min. Max. Std. Dev. p-value (W) Fold-Enrichment TP Rate
Limma 134 10 0.0295 5.0410 5 0 17 2.1852 <0.0001 1.9837 0.0746
ML 168 11 0.0520 6.3211 6 0 22 2.4421 <0.0001 1.7402 0.0655
ML ∪ Limma 246 14 0.0805 9.2609 9 0 25 2.9426 <0.0001 1.5117 0.0569
PD_02 1437 73 0.0034 55.4259 55 25 87 6.6392 <0.0001 1.3171 0.0508
PD_07 494 26 0.0512 18.5957 18 2 41 4.1038 <0.0001 1.3982 0.0526
PD_02 ∪ PD_07 1931 99 0.0003 72.6709 73 37 112 7.3516 <0.0001 1.3623 0.0513
Concensus 50 7 0.0025 1.8817 2 0 10 1.3407 <0.0001 3.7200 0.1400
n: number or genes in the prioritized PD module; m: number of known PD related genes in GAD found in the prioritized module; p-value: hypergeometric probability of
finding by chance k or more known PD related genes in a set of n prioritized genes; Mean/Median/Min./Max./Std. Dev.: average/median/minimum/maximum/standard
deviation of the number of known PD related genes in GAD included in randomly selected gene sets with the same number of genes as the corresponding set of
prioritized genes; Fold-enrichment: fold difference between m and Mean (Fold-enrichment =m/Mean); TP Rate: ratio of known PD related genes in n (TP Rate =m/n)
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and represents the ratio of disease-unrelated genes in
the total background gene list.
On the other hand, the enrichment factor (EF) takes
into account the improvement of the hit rate by a gene
prioritization protocol compared to a random selection.
This metric has the advantage of answering the question:
how enriched in known disease-related genes, the set of
n genes that I prioritize will be, compared to the situ-





where n is the number of genes in the filtered fraction
(χ) and m is the number of known disease-related genes
retrieved at this fraction, being χ determined by the quo-
tient between n and N (χ = n/N). The maximum value
that EF can take is 1/χ if χ ≥M/N, N/M if χ <M/N, and
the minimum value is zero [17].
However, the “early recognition” ability of a
prioritization tool is encoded by just a few enrichment
metrics such as the robust initial enhancement (RIE)
and the Boltzmann-enhanced discrimination of ROC
(BEDROC) metrics [17]. The RIE metric describes how
many times the distribution of the ranks for known
disease-related genes caused by a prioritization protocol













The parameter α is used to assign a higher weight
(and so a higher contribution to the RIE metric) to
known disease-related genes ranked at the beginning
than those at the end of the ordered list and can be
interpreted as the fraction of the list where the weight is
important. Specifically, in this work the RIE and also EF
and BEDROC metrics were evaluated at χ = 1 %/5 %/
10 %/20 %, which corresponds to values of α = 160.9/
32.2/16.1/8, respectively.
However, like EF, RIE depends on N, Ra and α, which
hampers its use in datasets of different size and compos-
ition. The other limitation is that unlike ROC, RIE nei-
ther provides a probabilistic interpretation nor a
measurement of the enrichment performance above all
thresholds [66].
In order to derive a new metric overcoming these





RIEmin and RIEmax are obtained when all the known
disease-related genes are at the beginning and at the end
of the ordered list, respectively.
RIEmin ¼ 1−e
αRa
Ra 1−eαð Þ ð8Þ
RIEmax ¼ 1−e
−αRa
Ra 1−e−αð Þ ð9Þ
The BEDROC metric is a generalization of the ROC
metric that includes a decreasing exponential weighting
function that adapts it for use in early recognition prob-
lems. This metric can be interpreted as the probability
that a known disease-related gene ranked by a
prioritization protocol will be found before a gene that
would come from a hypothetical exponential probability
distribution function with parameter α. Thus, BEDROC
should be understood as a “prioritization usefulness
scale” [17].
From the seven prioritization strategies being com-
pared, in Table 8 we estimate and compare the respect-
ive overall enrichment and early recognition ability of
those four providing a ranked list of genes through all or
part of the initial background of 8477 candidate genes.
The ranking provided through the full list of 8477
genes by each strategy is defined by the respective scor-
ing factor employed in the gene prioritization process.
Since just a subset of genes is prioritized by each
Table 8 Overall enrichment and early recognition metrics of
the four prioritization strategies considered
Limma ML ML-Limma Consensus
Classic Enrichment Metrics
AUAC 0.498 0.502 0.495 0.540
ROC 0.498 0.502 0.495 0.541
EF1% 2.855 2.521 2.847 3.164
EF5% 1.449 1.387 1.007 1.512
EF10% 1.038 1.385 0.913 1.510
EF20% 0.975 1.054 1.054 1.321
Early Recognition Metrics
RIE1% 2.452 2.213 2.403 2.577
RIE5% 1.286 1.438 1.157 1.583
RIE10% 1.089 1.225 1.044 1.400
RIE20% 1.021 1.085 1.008 1.230
BEDROC1% 0.094 0.086 0.094 0.099
BEDROC5% 0.091 0.102 0.083 0.113
BEDROC10% 0.131 0.147 0.125 0.168
BEDROC20% 0.216 0.230 0.214 0.262
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strategy, only this fraction is ranked and the remaining
genes in the full list of 8477 genes are randomized. The
rationale of such a experiment design is to resemble as
much as possible the respective prioritization strategy.
This randomization strategy is prefered over just to
evaluate the respective metrics on the respective priori-
tized genes set in order to avoid the saturation effect
present in small sets with a high ratio of known disease-
related genes [17]. The goal here is to evaluate the ability
of each prioritization strategy to retrieve the highest
fraction possible of those 319 known PD relevant genes
in the earliest possible fraction of the respective ordered
list. The exact composition of the four respective lists
(including ranking and aleatorization rules) is detailed in
the supplementary information.
All the values corresponding to AUAC and ROC met-
rics provided in Table 8 are close to 0.5, reflecting that
the overall enrichment ability of the four prioritization
strategies is not better than a random selection. This re-
sult, although expected due to the fact that >90 % of the
candidate genes are randomized must not be interpreted
as a lack of utility of the prioritization strategies. Instead,
the real estimation of their utility must focuse on their
early recognition ability.
The corresponding values of EF at the top frac-
tions studied (1, 5, 10, and 20 %) as well as the early
recognition metrics (RIE, and BEDROC) show that
the Consensus strategy compares favorably over the
rest of strategies considered, but the difference looks
minimal. However, the use of biologically relevant
information from PD_02 and PD_07 highlights the
advantages of using the Consensus strategy. The
comparative overall enrichment and early recognition
performance of the four prioritization strategies can
be visually confirmed on Fig. 3. As can be noted in
Fig. 3b, the enrichment performance of the Consen-
sus strategy clearly outperforms the other three
strategies on the top 20 % fraction of the list of
8477 genes considered. The same trend is confirmed
in the top 1 % fraction (see Fig. 3c), the most rele-
vant fraction to consider for early recognition assess-
ment [16].
Finally, we evaluated whether each of these prioritization
methods ranks a set of known PD genes significantly early
than an alternative method. For this, we applied a Wil-
coxon signed rank test to compare the ranking provided by
the four approaches under study (Limma, ML, ML-Limma
and Consensus) for the 100 % and the top 20 %/10 %/5 %
of the 319 PD genes collected from GAD. From this ana-
lysis is possible to note that although there is not an evident
difference between the early recognition metrics of the four
approaches, the consensus strategy ranks the PD genes sig-
nificantly early than the other three approaches (Limma,
ML and ML- Limma) in all the fractions analyzed [100 %
(319 PD Genes in GAD), top 20 % (top 64 PD genes), top
10 % (top 32 PD genes) and top 5 % (top 16 PD genes)].
Only the ranking provided by the consensus strategy
for the top 16 PD genes (top 5 %) was not signifi-
cantly better than the ranking provided by Limma.
See Table 9 for details.
Biological Relevance. Since the final 50 genes comes
from the intersection of the prioritizations made by
Limma, WGCNA modules, and specially ML, a reduced
statistical significance of their biological processes
should be expected too, similarly to ML. Most of the top
enriched GO terms in the biological process enrichment
analysis are associated with PD: dopamine (DA) metab-
olism [59–63, 67–80]; prepulse inhibition (PPI) [81–86];
Fig. 3 Accumulation curves of the four prioritization strategies considered. Overall enrichment represented by the accumulation curve for the full
set of 8477 background genes for the respective prioritization strategies (a). Zoom of the top 20 %/1 % fraction of the ordered list providing information
on the early recognition ability of the respective prioritization strategies (b/c)
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metal ion transport and pigmentation [87–96]. None of
the biological processes is statistically significant by
using an FDR adjusted p-value < 0.05 as significance cut-
off. See details in the supplementary information. How-
ever, from the top ten GO terms only one is directly
related with dopamine metabolism pointing to a reduced
dopamine bias.
Additionally, an exhaustive literature search was con-
ducted in order to find direct or indirect evidence of the
association with PD of each of the 50 genes prioritized.
As “direct evidence” we considered scientific publica-
tions reporting a relationship (i.e. mutation, expression
or knockout) between the gene and PD. As “indirect evi-
dence” we considered scientific publications reporting a
theoretical (i.e. system biology) or experimental (i.e. mu-
tation, expression, knockout) evidence of the association
of the gene with already known targets or biological pro-
cesses known to be related with PD pathogenesis.
The microarrays used in our study as raw data corres-
pond to references [45–47, 53, 97]. No result coming
from these studies only was used as “evidence”. How-
ever, studies performing system biology analysis which
include also our microarrays were considered because
the strategy for data exploration was different and there-
fore we don’t necessarily have to agree in the establish-
ment of genes-diseases association. However, even those
studies were considered as “indirect evidence”. Any
studies carried on in different microarrays and reporting
a down/up regulation were considered also but as “indir-
ect evidence”.
The literature review conducted evidenced that 20 out of
the 50 candidate genes were directly associated with PD
(SLC18A2; AGTR1; GBE1; PDCD2; ALDH1A1; SLC6A3;
TH; HIST1H2BD; DRD2; EN1; TRIM36; FABP7; PTPRN2;
VWA5A; ITPR1; CACNB3; CHORDC1; NDUFA9; RGS4;
SNRNP70). Additionally, indirect evidence of association
with PD was found for another 8 genes (CCNH; DLK1;
PCDH8; SLIT1; BMI1; DLD; PBX1; INSM), which are po-
tentially new therapeutic targets or biomarkers for PD. De-
tails on the direct or indirect literature evidence supporting
the association with PD of many of the 50 genes prioritized
by our consensus strategy are provided in Table 10.
As previously mentioned, the most relevant feature of
the consensus gene prioritization strategy proposed is the
early recognition ability evidenced [17]. It is significant
that the first 5 genes prioritized (first 10 %) could be con-
firmed with direct literature evidence. Finally, it is worthy
to note that based on the hypergeometric test it is possible
to assert that the identification of 20 or more genes out of
up to 2402 known PD related genes in a set of 50 priori-
tized genes is still significantly distant from being a ran-
dom selection (p-value = 0.049867). That is, considering
that an additional set of genes apart of those currently re-
ported in GAD can be relevant for PD but unreported up
today, the prioritized list of 50 genes is still statistically sig-
nificant even in the case that the actual (unknown) set of
PD relevant genes would be more than 7-fold (2402) those
currently reported in GAD (319).
Considering the above mentioned in addition to the
reduced size of the final set of genes prioritized by the
consensus strategy we conducted an additional analysis.
This analysis was based on the construction of a func-
tional interaction network with the aid of the Search
Tool for the Retrieval of Interacting Genes/Proteins
(STRING) [98, 99] from this final set of 50 genes priori-
tized with the consensus strategy (actually less because
some of these genes don’t have reported interaction in
our space) and 100 additional interacting genes with a
confidence score higher than 0.7. This network was
imported into Cytoscape [100] and each gene node was
Table 9 Results of the Wilcoxon signed rank test conducted to
compare the ranking provided by the four approaches under
study
319 PD Genes in GAD (100 %)
Limma ML ML-Limma Consensus
Limma (−−−) 2.62E-09 2.85E-01 2.79E-62
ML 2.62E-09 (−−−) 1.16E-01 4.36E-47
ML-Limma 2.85E-01 1.16E-01 (−−−) 4.27E-64
Consensus 2.79E-62 4.36E-47 4.27E-64 (−−−)
64 Top Ranked PD Genes in GAD (Top 20 %)
Limma ML ML-Limma Consensus
Limma (−−−) 1.84E-05 6.09E-01 6.81E-09
ML 1.84E-05 (−−−) 1.21E-07 1.69E-06
ML-Limma 6.09E-01 1.21E-07 (−−−) 1.24E-12
Consensus 6.81E-09 1.69E-06 1.24E-12 (−−−)
32 Top Ranked PD Genes in GAD (Top 10 %)
Limma ML ML-Limma Consensus
Limma (−−−) 7.19E-01 5.23E-04 1.19E-02
ML 7.19E-01 (−−−) 7.25E-02 3.11E-02
ML-Limma 5.23E-04 7.25E-02 (−−−) 1.38E-05
Consensus 1.19E-02 3.11E-02 1.38E-05 (−−−)
16 Top Ranked PD Genes in GAD (Top 5 %)
Limma ML ML-Limma Consensus
Limma (−−−) 6.06E-01 4.23E-01 3.02E-01
ML 6.06E-01 (−−−) 3.02E-01 1.95E-03
ML-Limma 4.23E-01 3.02E-01 (−−−) 4.33E-02
Consensus 3.02E-01 1.95E-03 4.33E-02 (−−−)
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SLC18A2 1 0 Several studies reported the association between SLC18A2 and PD [117–121]. In humans, the involvement of
SLC18A2 in PD pathogenesis is supported by positron emission tomography studies showing significantly
lower SLC18A2 densities in the putamen, caudate, and SN of PD patients [122–125]. Its potential as PD
biomarker [118] or even as a PD pharmacological target [126] have also been suggested. A method of
diagnosing PD comprising a set of differentially expressed genes including SLC18A2 was patented [127].
AGTR1 1 0 AGTR1 have been significantly and consistently downregulated in several PD microarray studies
[46, 47, 53, 128, 129]. Additionally, the protective effects on dopaminergic neurons of AGTR1
inhibitors have been well documented [130–136] highlighting the role of AGTR1 as a potential
pharmacological target in PD.
GBE1 1 0 GBE1 has been found to be downregulated in gene expression profiling studies of human substantia
nigra pars compacta from PD patients employing high density microarrays [121, 137]. A method of
diagnosing PD comprising a set of differentially expressed genes including GBE1 was patented [127].
PDCD2 1 0 The isoform 1 of PDCD2 was found to be ubiquitinated by parkin and increased in the substantia nigra of
patients with both autosomal recessive and sporadic PD [138].
ALDH1A1 1 0 ALDH1A1 has been found to be significantly and consistently downregulated in several PD microarray
studies [46, 47, 53, 121, 128, 129, 137, 139] highlighting DA metabolism dysfunction resulting in oxidative
stress and most probably leading to neuronal cell death. Two methods of diagnosing PD comprising a set
of differentially expressed genes including ALDH1A1 were patented [127, 140].
CCNH 0 1 So far, cyclin H (CCNH) has not been directly linked to the pathogenesis of PD. However, the cyclin-
dependent kinase 5 (CDK5) was found to act as a mediator of dopaminergic neuron loss in a mouse
model of Parkinson’s disease [141], pointing the potential role of CCNH as a novel and unexplored PD
biomarker.
NRXN3 0 0 No association between NRXN3 and PD was found.
SLC6A3 1 0 A combined analysis of published case–control genetic associations between SLC6A3 and PD involving several
ethnicities provided evidences of the role of SLC6A3 as a modest but significant risk factor for PD [142].
DLK1 0 1 No direct associations between DLK1 and PD have been reported. However, through a combined gene
expression microarray study in NURR1(−/−) mice DLK1 was identified as novel NURR1 target gene in
meso-diencephalic DA neurons [143]. NURR1 (also known as NR4A2) encodes a member of the steroid-
thyroid hormone-retinoid receptor superfamily [144]. Mutations in this gene have been associated with
disorders related to dopaminergic dysfunction including PD [145–163].
GPR161 0 0 No association between GPR161 and PD was found.
SCN3B 0 0 No association between SCN3B and PD was found.
TH 1 0 TH has been largely associated with PD [164–167].
PCDH8 0 1 No direct association between PCDH8 and PD was found unless a network-based systems biology study
utilizing several PD-related microarray gene expression datasets and biomolecular networks [168].
ORC5 0 0 No association between ORC5 and PD was found.
HECA 0 0 No association between HECA and PD was found.
SLIT1 0 1 No direct association between SLIT1 and PD was found. However, the axonal growth inhibition of
fetal and embryonic stem cell-derived dopaminergic neurons reported for SLIT1 [169] suggest an
indirect association with PD.
BMI1 0 1 Although BMI1 has not been directly associated with PD a previous study demonstrated that it is required in
neurons to suppress apoptosis and the induction of a premature aging-like program characterized by reduced
antioxidant defenses [170]. These findings provide a molecular mechanism explaining how BMI1 regulates free
radical concentrations and reveal the biological impact of BMI1 deficiency on neuronal survival and aging. The
activity of BMI1 against mitochondrial ROS may be also relevant to age-associated neurodegenerative diseases
where cell death is apparently mediated by oxidative damage, such as in Parkinson disease [171].
QPCT 0 0 No association between QPCT and PD was found.
DLD 0 1 No direct association between DLD and PD was found. However, mice that are deficient in DLD [172]
exhibited an increased vulnerability to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) [173], which
have been proposed for use in models of PD [174]. DLD is a critical subunit of key mitochondrial enzyme
complexes such as the ketoglutarate dehydrogenase complex (KGDHC) and the pyruvate dehydrogenase
complex (PDHC) [175]. Altered energy metabolism, including reductions in KGDHC and PDHC are
characteristic of many neurodegenerative disorders including PD [176, 177].
HIST1H2BD 1 0 HIST1H2BD was found to be significantly and differentially expressed in 20 out of the 21 brain regions
studied in a multiregional gene expression analysis in postmortem brain coming from 23 control and 22
PD cases [178]. A method of diagnosing PD comprising a set of differentially expressed genes including
HIST1H2BD was patented [179].
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Table 10 Literature evidence of the association with PD for the 50 genes prioritized with the consensus strategy (Continued)
PBX1 0 1 No direct association between PBX1 and PD was found. However, the expression of PBX1 in dopaminergic
neurons make it an important player in defining the axonal guidance of the midbrain dopaminergic neurons,
with possible implications for the normal physiology of the nigro-striatal system as well as processes related
to the degeneration of neurons during the course of PD [180].
SRP72 0 0 No association between SRP72 and PD was found.
DRD2 1 0 DRD2 has been largely associated with PD [181–194].
EN1 1 0 Several studies have reported significant associations between EN1 and PD [195–197].
TRIM36 1 0 TRIM36 has been found to be downregulated in a gene expression profiling study of human substantia
nigra pars compacta from PD patients employing high density microarrays [137]. A method of diagnosing
PD comprising a set of differentially expressed genes including TRIM36 was patented [127].
INSM1 0 1 Although INSM1 has not been directly associated with PD a previous study demonstrated that it
is involved on the interrelation of odor and motor changes probably caused by a Mn-induced
dopaminergic dysregulation affecting both functions [198]. In this study was found that the
rs2871776 G allele, which was associated with the worst effect of Mn on motor coordination, was
linked to alteration of a binding site for the transcription factor INSM1. This gene plays an important role in the
developing CNS, and especially of olfactory progenitors, as shown in mouse [199] and human [200]
embryos. Olfactory impairment is a highly recurrent non-motor dysfunction in PD and is considered
an early predictive sign of neurodegeneration [201–203].
MDH2 0 0 No association between MDH2 and PD was found.
CIRBP 0 0 No association between CIRBP and PD was found.
FABP7 1 0 A recent study reported that FABP7 levels were elevated in serum of 35 % of the patients with PD and
only in 2 % of the healthy controls, suggesting the role of FABP7 as a potential biomarker for PD [204].
FABP7 was also identified as a promising candidate in a previous quantitative trait loci (QTL) study
conducted to identify genes that mediate PPI in mice [205]. This finding was confirmed in a further
experiment where FABP7-deficient mice showed decreased PPI. PPI deficiencies is considered a characteristic
indicator of schizophrenia [82], but is also deficient in PD patients [206, 207].
PTPRN2 1 0 PTPRN2 has been found to be downregulated in a gene expression profiling study of human substantia
nigra pars compacta from PD patients employing high density microarrays [137]. A method of diagnosing
PD comprising a set of differentially expressed genes including PTPRN2 was patented [127].
PSMG1 0 0 No association between PSMG1 and PD was found.
VWA5A 1 0 VWA5A was associated with PD through a genome-wide genotyping study in PD and neurologically nor-
mal controls [208].
ITPR1 1 0 Kitamura et al. [209] reported since 1989 that ITPR1 binding sites were reduced by about 50 % in several
brain regions of PD patients (caudate nucleus, putamen, and pallidum) as compared to findings in the
age-matched controls, suggesting a probable implication of ITPR1 in PD.
BAI3 0 0 No association between BAI3 and PD was found.
CPT1B 0 0 No association between CPT1B and PD was found.
CACNB3 1 0 The calcium channel subunit b3 (CACNB3), the ATPase type 13A2 (PARK9), and several subunits of Ca2+
transporting ATPases (ATP2A3, ATP2B2, and ATP2C1) were downregulated in PD further substantiating the
involvement of a deficit in organelle function and of Ca2+ sequestering.
ACP2 0 0 No association between ACP2 and PD was found.
CHORDC1 1 0 CHORDC1 was found to be significantly and differentially expressed in 19 out of the 21 brain regions
studied in a multiregional gene expression analysis in postmortem brain coming from 23 control and 22
PD cases [178]. A method of diagnosing PD comprising a set of differentially expressed genes including
CHORDC1 was patented [179].
SHOC2 0 0 No association between SHOC2 and PD was found.
VBP1 0 0 No association between VBP1 and PD was found.
PPM1B 0 0 No association between PPM1B and PD was found.
YME1L1 0 0 No association between YME1L1 and PD was found.
NDUFA9 1 0 NDUFA9 is included in the KEGG Parkinson’s Disease Pathway (http://www.genome.jp/dbget-bin/
www_bget?pathway+hsa05012).
TRAPPC2L 0 0 No association between TRAPPC2L and PD was found.
HIST1H2AC 0 0 No association between HIST1H2AC and PD was found.
RGS4 1 0 RGS4 was found to be significantly and differentially expressed in several brain areas of postmortem samples
coming from PD patients in comparison to control samples [53]. On the other hand, experiments in mice with
reserpine-induced acute DA depletion suggest that RGS4-dependent attenuation of interneuronal autoreceptor
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labeled in order to differentiate those genes in the 50
genes prioritized with the consensus strategy from the
100 additional interacting genes added with STRING.
The resultant network representation in provided in the
supplementary information (see Additional file 5).
This network includes ubiquitin C (UBC), which ap-
pears as a central gene connecting most of the genes in-
cluded in the network. Although the role of UBC and
related genes/proteins in PD through biological process
such as protein synthesis, folding and degradation has
Fig. 4 Functional interaction network of the final set of 50 genes prioritized with the consensus strategy and 100 additional interacting genes.
Each gene node was labeled in order to differentiate those genes in the 50 genes prioritized with the consensus strategy from the 100 additional
interacting genes (labeled in gray). Genes with direct, indirect and no literature evidences of association with PD among the 50 genes prioritized
with the consensus strategy were labeled in red, yellow and blue, respectively. Those genes among the 100 additional interacting genes included
in the KEGG PD pathway were labeled in green
Table 10 Literature evidence of the association with PD for the 50 genes prioritized with the consensus strategy (Continued)
signaling is a major factor in the elevation of striatal acetylcholine release in PD [210]. Lerner and Kreitzer [211] also
identified RGS4 as a key link between DA 2/adenosine 2A signaling and endocannabinoid mobilization pathways.
In addition, in contrast to wild-type mice, RGS4 deficient mice exhibited normal endocannabinoid-dependent
long-term depression after DA depletion and were significantly less impaired in the 6-OHDA model of PD. Taken
together, these results suggest that inhibition of RGS4 may be an effective nondopaminergic strategy for treating
Parkinson’s disease. Finally, RGS4 was recently found to be involved in the generation of abnormal involuntary
movements in the unilateral 6-hydroxydopamine (6-OHDA)-lesioned rat model of PD [212].
CRYZL1 0 0 No association between CRYZL1 and PD was found.
RCN2 0 0 No association between RCN2 and PD was found.
SNRNP70 1 0 SNRNP70 was associated with woman affected by PD in an association study of four common
polymorphisms in the DJ1 gene and PD involving 416 PD probands and their unaffected siblings
matched by gender and closest age [213].
VPS4B 0 0 No association between VPS4B and PD was found.
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long been established [52, 101, 102], their hub nature in
our network could induce a connectivity bias at the time
to perform further visual interaction or biological pro-
cesses enrichment analysis. So UBC was removed from
the network previous to conduct the mentioned analysis.
Details on the biological processes enrichment analysis
are provided in the supplementary information. The
functional interaction network after removing UBC is
provided in Fig. 4.
From the literature search 22 genes (NRXN3, GPR161,
SCN3B, ORC5, HECA, QPCT, SRP72, MDH2, CIRBP,
PSMG1, BAI3, CPT1B, ACP2, SHOC2, VBP1, PPM1B,
YME1L1, TRAPPC2L, HIST1H2AC, CRYZL1, RCN2,
VPS4B) were no associated with PD which challenges
the prioritization quality. However; as can be noted in
the functional interaction network (see Fig. 5), many of
these genes (represented as blue nodes) have a func-
tional connection with important biological processes or
genes directly related with PD (represented as red or
green nodes). It has to be mentioned that 10 out of these
22 genes (ACP2, BAI3, CRYZL1, GPR161, HECA,
NRXN3, QPCT, SCN3B, TRAPPC2L, VPS4B) has no
interactions in this space and therefore are not included
in this network and that all disconnected clusters and/or
nodes in this network are actually connected through
UBC gene as can be confirmed in the full network pro-
vided in the supplementary information.
An important finding in this network is that even when
PPARGC1A was not identified in our study, several genes
were found to be direct interactors, and biological process
directly related with this gene are clearly present in our
prioritized genes. Specifically, can be confirmed that
PPARGC1A is connected through short paths with several
of the final 50 genes with reported associations with PD
(such as TH, AGTR1 and FABP7) or other without
current associations with the disease such as PPM1B or
CPT1B. On the other hand, the GO enrichment analysis
based on this functional interaction network includes sev-
eral biological process related with the PPARGC1A func-
tion. See details in the supplementary information.
The GO enrichment analysis was conducted (based on
DAVID) in order to access to significant biological
process encoded by the set of genes in this functional
interaction network. Contrary to what was expected due
Fig. 5 Functional interaction network comprising gene sets prioritized by Limma and ML, respectively. The genes prioritized by ML/Limma only
are represented by yellow/green nodes, while those genes prioritized by both approaches (ML and Limma) are represented by blue nodes. Genes
in the KEGG Dopaminergic Synapse Pathway/KEGG Parkinson’s Disease Pathway are represented by olive/red nodes, while those genes included
in both pathways (Dopaminergic Synapse and Parkinson’s Disease) are represented by orange nodes
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to the risk of the “dopamine bias”, from this analysis is
clear the highly significant role of RNA splicing [103]
(through several mechanisms) and energy metabolism
[46–49, 53] compared with the dopamine metabolism
process. This last, although statistically significant was
placed well below the two former biological process
which on the other hand, have been well associated to
PD and unrelated to dopamine metabolism. Again, this
suggests that the consensus strategy proposed in this
work is not affected by the dopamine bias.
Dopamine Bias. As declared from the beginning, the
dopamine bias was considered in the discussion of every
prioritization method applied. A last experiment was ex-
pressly conducted to evaluate this important issue. For
this, a functional interaction network was constructed
with the aid of STRING from the set of 246 unique
genes coming from the union of ML and Limma priori-
tizations (see Fig. 5).
If we look for those genes in the KEGG Dopaminergic
Synapse Pathway (129 genes in the DA Pathway) and in
the KEGG Parkinson’s Disease Pathway (142 genes in
the PD Pathway) comprised in the set of 246 unique
genes coming from the union of ML and Limma priori-
tizations, it is possible to note that only 4.47 % (11 DA
genes out of 246) of this set corresponds to the DA
pathway, which indicates an insignificant risk of “dopa-
mine bias” for this set. If we also consider that four out
of this eleven DA genes are involved in the PD pathway
such risk becomes really insignificant. More importantly,
the set of 56 genes shared by ML and Limma prioritiza-
tions only involves five (DRD2, TH, SLC6A3 and
SLC18A2) out of the 129 genes in the KEGG DA path-
way. Only one (ITPR1) of these five genes was exclusive
of the DA pathway, the other four genes were also in-
cluded in the KEGG PD pathway. This is a clear indica-
tor of the benefits provided by the integration of
conceptually different approaches regarding to avoid the
“dopamine bias”. All this information can be visually
confirmed in the interaction network of genes coming
from ML and Limma prioritizations provided in Fig. 4.
As can be observed in this figure, the ML prioritization
is less prone to be affected by the “dopamine bias” which
suggest a key role of this approach in reducing such risk.
Finally, only six genes were excluded from the 56
genes from the ML-Limma prioritization (CLK1,
DDX17, LRP2, NDRG1, SESN1 and SYT17) by concur-
rently considering the significant PD modules identified
in the WGCN analysis (PD_02 and PD_07). Only five
out of the 50 prioritized genes were present in the
KEGG DA pathway and four out this five dopamine-
related genes were included in the KEEG PD pathway.
So, from this analysis we can conclude that the consen-
sus strategy proposed in this work is not affected by the
“dopamine bias”. See details in Table 11.
Conclusions
A hydrid gene prioritization approach was applied to PD.
Specifically, the set of 50 genes prioritized with the pro-
posed consensus strategy was statistically significant, bio-
logically relevant, highly enriched with know PD related
genes and exhibited an excelent early recognition ability. In
addition to 20 know PD related genes, eight potentially
novel PD biomarkers or therapeutic targets (CCNH, DLK1,
PCDH8, SLIT1, DLD, PBX1, INSM1, and BMI1) were
identified. Additionally, a statistically rigorous approach of
standard use in chemoinformatics was proposed to evaluate
the early recognition ability of gene prioritization tools. We
also demonstrated that the proper combination of several
sources of information is a suitable strategy for module
prioritization in co-expression networks analysis. Finally, it
is possible to assert that the proposed consensus strategy
represents an efficient and biologically relevant approach
for gene prioritization tasks, providing a valuable decision-
making tool for the study of PD pathogenesis and the de-
velopment of disease-modifying PD therapeutics.
Additional files
Additional file 1: 1) Figure S1. Functional interaction network of the
final set of 50 genes prioritized with the consensus strategy and 100
additional interacting genes including UBC. 2) Table S1. Samples
distribution used for ML analysis. 3) Table S2. Sets of PD relevant genes
identified by the thirteen ML classification algorithms. 4) Table S3.
Details on the 50 genes prioritized by means of the proposed consensus
strategy. 5) Attribute evaluators used in the consensus ranking analysis. 6)
Hypergeometric probability test details. 7) PD related terms in GAD used
to identify the set of 513 PD related genes. 8) Composition of the sorted
genes lists corresponding to the four prioritization strategies (Limma, ML,
ML-Limma, and Consensus). (DOCX 2196 kb)
Additional file 2: Normalized expression values of the 8477 common
genes for each of the 102 samples, sample and study identifiers, disease
factor (PD or HC), as well as the distribution of training and test samples.
(TXT 10084 kb)
Additional file 3: Details of the reduced gene set by using the mRMR
software. (TXT 54 kb)
Table 11 Number of genes in the KEGG DA Pathway, KEGG PD
Pathway, and both KEGG DA and PD Pathways in the respective
prioritized gene sets
PrioritizationApproach N n(%) %
DA PD DA-PD DA-PD/DA
ML ∪ Limma 246 11(4.47) 6(2.44) 4(1.63) 36.36
ML 168 7(4.17) 5(2.98) 4(2.38) 57.14
Limma 134 9(6.72) 6(4.48) 4(2.99) 44.44
ML ∩ Limma 56 5(8.93) 5(8.93) 4(7.14) 80.00
Only-ML 112 2(1.79) 0(0.00) 0(0.00) 0.00
Only-Limma 78 4(5.13) 1(1.28) 0(0.00) 0.00
Consensus 50 5(10.00) 5(10.00) 4(8.00) 80.00
N: Number of genes prioritized; n: number; %: percentage; DA: genes in the
KEGG Dopaminergic Synapse Pathway; PD: genes in the KEGG Parkinson’s
Disease Pathway; DA-PD: genes in the KEGG Dopaminergic Synapse Pathway
and the KEGG Parkinson’s Disease Pathway
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Additional file 4: Details on the genes sets prioritized by the respective
approaches. (TXT 23 kb)
Additional file 5: 1) Results of the Limma prioritization for the top 1016
genes with uncorrected p-values < 0.05. 2) Results of the gene ontology
(biological process) enrichment analysis for the top 134 genes prioritized
with Limma with FDR corrected p-values < 0.05. 3) Results of the gene
ontology (biological process) enrichment analysis for the top 1016 genes
prioritized with Limma with uncorrected p-values < 0.05. 4) List of the 168
genes prioritized with machine learning. 5) Results of the gene ontology
(biological process) enrichment analysis for the 168 genes prioritized with
machine learning. 6) Results of the gene ontology (biological process)
enrichment analysis for the 1437 genes included in the co-expression
module PD_02. 7) Results of the gene ontology (biological process)
enrichment analysis for the 494 genes included in the co-expression
module PD_07. 8) Results of the ToppCluster combined enrichment
analysis for the co-expression modules PD_02 and PD_07. 9) Results of
the gene ontology (biological process) enrichment analysis for the 50
genes prioritized with the consensus strategy and 100 additional interacting
genes included in the STRING functional interaction network. (XLSX 493 kb)
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